Physician profile
Julia Dudkiewicz
NPI 1588395909
$10,619.50
in general payments reported to CMS, 2019-2025
22 companies · $5,075 in 2025
The $5,075 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.90 · 2023: $1,838 · 2024: $3,683 · 2025: $5,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,595.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,932.16 | 2023-2025 | |
| Janssen Biotech, INC. | $1,493.28 | 2023-2025 | Tremfya, Simponi Aria |
| Arcutis Biotherapeutics, INC. | $1,090.64 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $993.98 | 2023-2025 | Nemluvio, Aklief, Twyneo |
| Pfizer INC. | $866.41 | 2023-2025 | |
| Lilly USA, LLC | $568.95 | 2023-2025 | Olumiant |
| Genzyme Corporation | $549.26 | 2023-2025 | |
| Botanix Sb INC | $495.40 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $449.15 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.26 | 2023-2025 | Spevigo |
| Sun Pharmaceutical Industries INC. | $308.51 | 2025 | |
| Verrica Pharmaceuticals INC. | $249.21 | 2024-2025 | Ycanth |
| Ucb, INC. | $248.28 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $245.34 | 2024 | Vtama |
| Amgen INC. | $225.84 | 2023-2025 | Otezla, Otezla |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $204.98 | 2023-2024 | Sotyktu |
| Organon LLC | $191.28 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $50.03 | 2023-2025 | |
| Incyte Corporation | $40.28 | 2025 | Opzelura, Opzelura |
| Biofrontera INC. | $23.90 | 2022 | |
| Strata Skin Sciences, INC. | $18.10 | 2025 | Xtrac |
| Mayne Pharma Commercial LLC | $14.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Dudkiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.